Endothelial-monocyte activating polypeptide ii (emap-ii), a biomarker for use in diagnosis and treatment of brain injury

Abstract

A diagnostic tool and method of diagnosing brain injury and brain injury type (traumatic vs. ischemic) by detecting the level of expression of endothelial monocyte-activating polypeptide II (EMAP II) and comparing to a control. An increase of EMAP II indicates the presence of traumatic brain injury and a decrease of EMAP II indicates the presence of ischemic brain injury. Detection of EMAPII can be done in brain tissue, biofluids such as cerebrospinal fluid or blood (including plasma and serum)

1 - 17 . (canceled) 
     
     
         18 . A protein screening device containing thereon a comparative information profile of Endothelial-monocyte activating polypeptide II (EMAP II) and/or p43 Endothelial-monocyte activating polypeptide II (p43/EMAP II) from three sources, said sources comprising a control patient with no brain injury, an approximately 24 hour post injury patient who has suffered ischemic brain injury and an approximately 24 hour post injury patient who has suffered traumatic brain injury, said protein screening device selected from the group consisting of a high-throughput immunoblotting device with comparative profile thereon, protein chip device with comparative profile thereon, Western Blott device with comparative profile thereon or ELISA device with comparative profile thereon; said protein screening device to facilitate the differential profiling of acute brain injuries to determine whether a patient has or has not suffered ischemic brain injury or traumatic brain injury. 
     
     
         19 . The protein screening device containing the comparative profile of  claim 18 , wherein said protein screening device's comparative profile has a profile for said traumatic brain injury with an increase of expression of EMAP II and/or p43/EMAP II of 1.6 to 1.8 fold relative to the control and a profile for said ischemic brain injury with a decrease of expression of EMAP II and/or p43/EMAP II of 2.1 to 2.3 fold relative to the control. 
     
     
         20 . The protein screening device of claim  14 , wherein said patient is a human. 
     
     
         21 . A protein screening device containing a comparative profile thereon of (a) Endothelial-monocyte activating polypeptide II (EMAP II) and/or p43 Endothelial-monocyte activating polypeptide II (p43/EMAP II), (b) Signal transducer and activator of transcription 3 (STAT3), and (c) PKA RII     β    from three sources, said sources comprising a control patient with no brain injury, an approximately 24 hour post injury patient who has suffered ischemic brain injury and an approximately 24 hour post injury patient who has suffered traumatic brain injury, said protein screening device with said comparative profile thereon selected from the group consisting of a high-throughput immunoblotting protein screening device with comparative profile thereon, protein chip protein screening device with comparative profile thereon, Western Blott protein screening device with comparative profile thereon or ELISA protein screening device with comparative profile thereon; said protein screening device with comparative profile thereon being useful as a diagnostic tool for diagnosing whether a patient has or has not suffered ischemic brain injury or traumatic brain injury. 
     
     
         22 . The protein screening device of  claim 18 , wherein each of said three sources were either blood plasma, brain tissue or cerebral spinal fluid. 
     
     
         23 . The protein screening device of  claim 21 , wherein each of said three sources were either blood plasma, brain tissue or cerebral spinal fluid. 
     
     
         24 . The protein screening device of  claim 20 , wherein said patient is a human patient.